1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
2
|
Burstein HJ, Temin S, Anderson H, Buchholz
TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky
AJ, et al: Adjuvant endocrine therapy for women with hormone
receptor-positive breast cancer: American Society of Clinical
Oncology clinical practice guideline focused update. J Clin Oncol.
32:2255–2269. 2014. View Article : Google Scholar : PubMed/NCBI
|
3
|
Lumachi F, Brunello A, Maruzzo M, Basso U
and Basso SM: Treatment of estrogen receptor-positive Breast
Cancer. Curr Med Chem. 20:596–604. 2013. View Article : Google Scholar : PubMed/NCBI
|
4
|
Davies C, Godwin J, Gray R, Clarke M,
Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, et al;
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Relevance of breast cancer hormone receptors and other factors to
the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of
randomised trials. Lancet. 378:771–784. 2011. View Article : Google Scholar : PubMed/NCBI
|
5
|
Kilker RL, Hartl MW, Rutherford TM and
Planas-Silva MD: Cyclin D1 expression is dependent on estrogen
receptor function in tamoxifen-resistant breast cancer cells. J
Steroid Biochem Mol Biol. 92:63–71. 2004. View Article : Google Scholar : PubMed/NCBI
|
6
|
Wegman P, Elingarami S, Carstensen J, Stål
O, Nordenskjöld B and Wingren S: Genetic variants of CYP3A5,
CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal
patients with breast cancer. Breast Cancer Res. 9:R72007.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Ghayad SE, Vendrell JA, Ben Larbi S,
Dumontet C, Bieche I and Cohen PA: Endocrine resistance associated
with activated ErbB system in breast cancer cells is reversed by
inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer.
126:545–562. 2010. View Article : Google Scholar
|
8
|
Lindberg K, Helguero LA, Omoto Y,
Gustafsson JA and Haldosén LA: Estrogen receptor β represses Akt
signaling in breast cancer cells via downregulation of HER2/HER3
and upregulation of PTEN: Implications for tamoxifen sensitivity.
Breast Cancer Res. 13:R432011. View
Article : Google Scholar
|
9
|
Normanno N, Di Maio M, De Maio E, De Luca
A, de Matteis A, Giordano A and Perrone F; NCI-Naple Breast Cancer
Group. Mechanisms of endocrine resistance and novel therapeutic
strategies in breast cancer. Endocr Relat Cancer. 12:721–747. 2005.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Ring A and Dowsett M: Mechanisms of
tamoxifen resistance. Endocr Relat Cancer. 11:643–658. 2004.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Knowlden JM, Gee JM, Seery LT, Farrow L,
Gullick WJ, Ellis IO, Blamey RW, Robertson JF and Nicholson RI:
c-erbB3 and c-erbB4 expression is a feature of the endocrine
responsive phenotype in clinical breast cancer. Oncogene.
17:1949–1957. 1998. View Article : Google Scholar : PubMed/NCBI
|
12
|
Fujiwara S, Ibusuki M, Yamamoto S,
Yamamoto Y and Iwase H: Association of ErbB1-4 expression in
invasive breast cancer with clinicopathological characteristics and
prognosis. Breast Cancer. 21:472–481. 2012. View Article : Google Scholar : PubMed/NCBI
|
13
|
Guler G, Iliopoulos D, Guler N, Himmetoglu
C, Hayran M and Huebner K: Wwox and Ap2gamma expression levels
predict tamoxifen response. Clin Cancer Res. 13:6115–6121. 2007.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Kainulainen V, Sundvall M, Määttä JA,
Santiestevan E, Klagsbrun M and Elenius K: A natural ErbB4 isoform
that does not activate phosphoinositide 3-kinase mediates
proliferation but not survival or chemotaxis. J Biol Chem.
275:8641–8649. 2000. View Article : Google Scholar : PubMed/NCBI
|
15
|
Elenius K, Corfas G, Paul S, Choi CJ, Rio
C, Plowman GD and Klagsbrun M: A novel juxtamembrane domain isoform
of HER4/ErbB4. Isoform-specific tissue distribution and
differential processing in response to phorbol ester. J Biol Chem.
272:26761–26768. 1997. View Article : Google Scholar : PubMed/NCBI
|
16
|
Elenius K, Choi CJ, Paul S, Santiestevan
E, Nishi E and Klagsbrun M: Characterization of a naturally
occurring ErbB4 isoform that does not bind or activate phosphatidyl
inositol 3-kinase. Oncogene. 18:2607–2615. 1999. View Article : Google Scholar : PubMed/NCBI
|
17
|
Muraoka-Cook RS, Sandahl MA, Strunk KE,
Miraglia LC, Husted C, Hunter DM, Elenius K, Chodosh LA and Earp HS
III: ErbB4 splice variants Cyt1 and Cyt2 differ by 16 amino acids
and exert opposing effects on the mammary epithelium in vivo. Mol
Cell Biol. 29:4935–4948. 2009. View Article : Google Scholar : PubMed/NCBI
|
18
|
Sundvall M, Veikkolainen V, Kurppa K,
Salah Z, Tvorogov D, van Zoelen EJ, Aqeilan R and Elenius K: Cell
death or survival promoted by alternative isoforms of ErbB4. Mol
Biol Cell. 21:4275–4286. 2010. View Article : Google Scholar : PubMed/NCBI
|
19
|
Sundvall M, Peri L, Määttä JA, Tvorogov D,
Paatero I, Savisalo M, Silvennoinen O, Yarden Y and Elenius K:
Differential nuclear localization and kinase activity of
alternative ErbB4 intracellular domains. Oncogene. 26:6905–6914.
2007. View Article : Google Scholar : PubMed/NCBI
|
20
|
Naresh A, Thor AD, Edgerton SM, Torkko KC,
Kumar R and Jones FE: The HER4/4ICD estrogen receptor coactivator
and BH3-only protein is an effector of tamoxifen-induced apoptosis.
Cancer Res. 68:6387–6395. 2008. View Article : Google Scholar : PubMed/NCBI
|
21
|
Naresh A, Long W, Vidal GA, Wimley WC,
Marrero L, Sartor CI, Tovey S, Cooke TG, Bartlett JM and Jones FE:
The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein
promoting apoptosis of breast cancer cells. Cancer Res.
66:6412–6420. 2006. View Article : Google Scholar : PubMed/NCBI
|
22
|
Thor AD, Edgerton SM and Jones FE:
Subcellular localization of the HER4 intracellular domain, 4ICD,
identifies distinct prognostic outcomes for breast cancer patients.
Am J Pathol. 175:1802–1809. 2009. View Article : Google Scholar : PubMed/NCBI
|
23
|
Rokicki J, Das PM, Giltnane JM, Wansbury
O, Rimm DL, Howard BA and Jones FE: The ERalpha coactivator,
HER4/4ICD, regulates progesterone receptor expression in normal and
malignant breast epithelium. Mol Cancer. 9:1502010. View Article : Google Scholar : PubMed/NCBI
|
24
|
Rutqvist LE and Johansson H: Long-term
follow-up of the randomized Stockholm trial on adjuvant tamoxifen
among post-menopausal patients with early stage breast cancer. Acta
Oncol. 46:133–145. 2007. View Article : Google Scholar
|
25
|
Subik K, Lee JF, Baxter L, Strzepek T,
Costello D, Crowley P, Xing L, Hung MC, Bonfiglio T, Hicks DG, et
al: The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and
AR by immunohistochemical analysis in breast cancer cell lines.
Breast Cancer (Auckl). 4:35–41. 2010.
|
26
|
Han W and Jones FE: HER4 selectively
coregulates estrogen stimulated genes associated with breast tumor
cell proliferation. Biochem Biophys Res Commun. 443:458–463. 2014.
View Article : Google Scholar :
|
27
|
Fujiwara S, Hung M, Yamamoto-Ibusuk CM,
Yamamoto Y, Yamamoto S, Tomiguchi M, Takeshita T, Hayashi M, Sueta
A and Iwase H: The localization of HER4 intracellular domain and
expression of its alternately-spliced isoforms have prognostic
significance in ER+ HER2− breast cancer.
Oncotarget. 5:3919–3930. 2014. View Article : Google Scholar : PubMed/NCBI
|
28
|
Barnes NL, Khavari S, Boland GP, Cramer A,
Knox WF and Bundred NJ: Absence of HER4 expression predicts
recurrence of ductal carcinoma in situ of the breast. Clin Cancer
Res. 11:2163–2168. 2005. View Article : Google Scholar : PubMed/NCBI
|
29
|
Hutcheson IR, Goddard L, Barrow D,
McClelland RA, Francies HE, Knowlden JM, Nicholson RI and Gee JM:
Fulvestrant-induced expression of ErbB3 and ErbB4 receptors
sensitizes oestrogen receptor-positive breast cancer cells to
heregulin β1. Breast Cancer Res. 13:R292011. View Article : Google Scholar
|
30
|
Revillion F, Pawlowski V, Lhotellier V,
Louchez MM and Peyrat JP: mRNA expression of the type I growth
factor receptors in the human breast cancer cells MCF-7: Regulation
by estradiol and tamoxifen. Anticancer Res. 23B:1455–1460.
2003.
|